New revelations about U.S. Rep. Tom Price’s financial entanglements could complicate Senate Republicans’ plan to swiftly confirm the Roswell Republican as President-elect Donald Trump’s health secretary in the new year.
Senate Democrats on Friday seized on a report from The Wall Street Journal that Price traded more than $300,000 in shares of health-related companies over the past four years while pushing legislation on Capitol Hill that could have had an impact on those businesses’ bottom lines.
The report thrusts into the spotlight Price’s ties to the medical community. It also raises new questions about potential conflicts of interest to which Price, an orthopedic surgeon, will need to answer during his Senate confirmation hearings that are expected to be held next month.
Publicly, Democrats took a measured tone Friday, but they signaled they plan to zero in on whether the timing of Price’s stock actions violate a 2012 insider trading law that bars members of Congress and their aides from buying stocks based on nonpublic information acquired in their positions.
Read more about Democrats’ plans, Price’s stock trading history and the reaction from Donald Trump’s transition team here.